Jonathan is a Venture Partner at Forbion.
He was previously Chief Business Officer at Dyne Therapeutics having contributed to the company's transformation into a leading muscle disease-focused company. Prior to Dyne, he held leadership roles at Editas Medicine, a clinical-stage biotech developing medicines for rare diseases based on CRISPR technology, and was a member of Boston Consulting Group’s healthcare practice.
